On April 1, 2022, INOVIQ Limited (ASX:IIQ) announced that it has expanded its collaboration with The University of Queensland (UQ) to develop a world-first exosome-based ovarian cancer screening test. The work involves using exosomes as a source of accurate biomarkers for ovarian cancer. Exosomes are a type of extracellular vesicle (EV) that are small particles (approximtely 30-150 nm in diameter) released by all cells into biofluids such as blood, urine, and saliva. Exosomes can contain different types of bioactive molecules such as DNAs, RNAs, proteins, and lipids that convey important information about their parent cell that can be used for the identification of biomarkers, diagnosis, and treatment of disease. INOVIQ’s EXO-NET technology efficiently captures exosomes from the blood to enable development of multi-omic diagnostic tests that combine the multiple biomarkers in an algorithm for the earlier and more accurate detection of various diseases such as cancer, inflammatory, metabolic, and neurodegenerative diseases.